Phase 4 challenge trial in healthy adults: 1 month after vaccination, PCV13 gave a non-significant reduction in serotype 3 colonisation vs placebo (56% vs 65%; RR 0.84, 0.70-1.01). PPV23 showed no protection; PCV13 cut serotype 6B colonisation at 6 months (RR 0.40).
RCTn = 407
Liatsikos et al. The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial